Rexford Industrial Realty Inc
Change company Symbol lookup
Select an option...
REXR-A Rexford Industrial Realty Inc
DPW DPW Holdings Inc
IWN iShares Russell 2000 Value ETF
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Growth
Company profile

Rexford Industrial Realty, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company is focused on owning and operating industrial properties in Southern California infill markets. Through its controlling interest in its Rexford Industrial Realty, L.P. (Operating Partnership) and its subsidiaries, it owns, manages, leases, acquires and develops industrial real estate principally located in Southern California infill markets, and, from time to time, acquire or provide mortgage debt secured by industrial property. It owns a portfolio of approximately 236 properties with approximately 29.9 million rentable square feet. In addition, it manages approximately 20 properties with approximately one million rentable square feet.

This security is a preferred stock
Closing Price
$25.22
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
19,621
0

SHAREHOLDER ALERT: FLDM GLNG BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

5:15 pm ET November 19, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 19, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Fluidigm Corporation (NASDAQ:FLDM)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fluidigm-corporation-loss-submission-form?prid=11093&wire=1Lead Plaintiff Deadline: November 20, 2020Class Period: February 7, 2019 - November 5, 2019

Allegations against FLDM include that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Golar LNG Limited (NASDAQ:GLNG)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/golar-lng-limited-loss-submission-form?prid=11093&wire=1Lead Plaintiff Deadline: November 23, 2020Class Period: April 30, 2020 - September 24, 2020

Allegations against GLNG include that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited ("Hygo"), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Biogen Inc. (NASDAQ:BIIB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biogen-inc-loss-submission-form?prid=11093&wire=1Lead Plaintiff Deadline: January 12, 2021Class Period: October 22, 2019 - November 6, 2019

Allegations against BIIB include that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com: https://www.accesswire.com/617687/SHAREHOLDER-ALERT-FLDM-GLNG-BIIB-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.